MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate – Business Wire (press release)
Business Wire (press release) |
MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate
Business Wire (press release) LONDON & NEW YORK–(BUSINESS WIRE)–MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx's gene therapy product candidate A002 for … |
